Revance Therapeutics, Inc. announced presentation of clinical data from the company’s BELMONT Phase 2 study of Daxibotulinumtoxin Injectable (RT002) at the 19th annual IMCAS (International Master Course on Aging Skin) World Congress, taking place at Palais des Congrès, Paris, France, January 26-29, 2017. BELMONT was the company’s Phase 2 active comparator, placebo-controlled, multi-center study to evaluate the safety, efficacy, and duration of effect of RT002 injectable for the treatment of glabellar (frown) lines.